High expression of ADAM8 correlates with poor prognosis in hepatocellular carcinoma
Authors:
- 8 August 2012
- journal article
- Published by Elsevier in The Surgeon
- Vol. 11 (2) , 67-71
Abstract
No abstract availableKeywords
This publication has 19 references indexed in Scilit:
- Hepatocellular carcinoma: current trends in worldwide epidemiology, risk factors, diagnosis and therapeuticsExpert Review of Gastroenterology & Hepatology, 2009
- TACE versus TAE as therapy for hepatocellular carcinomaExpert Review of Anticancer Therapy, 2008
- Hepatocellular carcinoma: prevention, detection and treatment … in the real worldInternal Medicine Journal, 2007
- Ectodomain Shedding of the Neural Recognition Molecule CHL1 by the Metalloprotease-disintegrin ADAM8 Promotes Neurite Outgrowth and Suppresses Neuronal Cell DeathJournal of Biological Chemistry, 2004
- Catalytic Activity of ADAM8, ADAM15, and MDC-L (ADAM28) on Synthetic Peptide Substrates and in Ectodomain Cleavage of CD23Journal of Biological Chemistry, 2003
- The ADAMs family of metalloproteases: multidomain proteins with multiple functionsGenes & Development, 2003
- The Metalloprotease Disintegrin ADAM8Journal of Biological Chemistry, 2002
- The ADAM gene family: surface proteins with adhesion and protease activityTrends in Genetics, 2000
- ADAM family proteins in the immune systemImmunology Today, 1999
- CD156 (Human ADAM8): Expression, Primary Amino Acid Sequence, and Gene LocationGenomics, 1997